Quick Answer
Travere Therapeutics, Inc. reported Total Assets of $605.19 million for the year ending 2025.
- Travere Therapeutics, Inc. showed an increase of +1.9% in Total Assets from 2024 to 2025.
- This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $3.9 thousand | Q2 2012: $3.9 thousand | Q3 2012: $3.9 thousand | Q4 2012: $3.9 thousand | Q1 2013: $4.95 million | Q2 2013: $2.67 million | Q3 2013: $21.36 million | Q1 2014: $94.05 million | Q2 2014: $155.54 million | Q3 2014: $145.93 million | Q1 2015: $415.99 million | Q2 2015: $425.14 million | Q3 2015: $511.63 million | Q1 2016: $507.10 million | Q2 2016: $533.97 million | Q3 2016: $532.42 million | Q1 2017: $510.38 million | Q2 2017: $507.13 million | Q3 2017: $520.51 million | Q1 2018: $500.79 million | Q2 2018: $491.14 million | Q3 2018: $716.19 million | Q1 2019: $667.67 million | Q2 2019: $647.57 million | Q3 2019: $613.82 million | Q1 2020: $573.06 million | Q2 2020: $678.69 million | Q3 2020: $692.22 million | Q1 2021: $764.05 million | Q2 2021: $746.77 million | Q3 2021: $775.08 million | Q1 2022: $828.41 million | Q2 2022: $779.49 million | Q3 2022: $726.22 million | Q1 2023: $808.23 million | Q2 2023: $736.43 million | Q3 2023: $832.85 million | Q1 2024: $663.55 million | Q2 2024: $551.12 million | Q3 2024: $504.41 million | Q1 2025: $548.80 million | Q2 2025: $555.31 million | Q3 2025: $538.58 million.
- Over the full 15 years of available data (2011 to 2025), Travere Therapeutics, Inc.'s Total Assets has grown by 3,092,342.5%.
- Historical annual values: Fiscal year 2025: $605.19 million | Fiscal year 2024: $594.13 million | Fiscal year 2023: $788.91 million | Fiscal year 2022: $672.59 million | Fiscal year 2021: $776.63 million | Fiscal year 2020: $607.44 million | Fiscal year 2019: $604.80 million | Fiscal year 2018: $709.16 million | Fiscal year 2017: $520.35 million | Fiscal year 2016: $525.28 million | Fiscal year 2015: $512.26 million | Fiscal year 2014: $135.47 million | Fiscal year 2013: $20.50 million | Fiscal year 2012: $2.39 million | Fiscal year 2011: $19.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: